Annovis Bio
ANVS
36 hedge funds and large institutions have $22.6M invested in Annovis Bio in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 5 closing their positions.
588% more call options, than puts
Call options by funds: $3.27M | Put options by funds: $476K
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
114% more capital invested
Capital invested by funds: $10.6M → $22.6M (+$12M)
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
20% more funds holding
Funds holding: 30 → 36 (+6)
0.59% less ownership
Funds ownership: 12.34% → 11.75% (-0.59%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$699K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$289K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$167K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$140K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$464K |
| 2 |
MFG
Merit Financial Group
Alpharetta,
Georgia
|
-$168K |
| 3 |
Koshinski Asset Management
Decatur,
Illinois
|
-$142K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$130K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$117K |
ANVS Hedge Fund Activity: Q4 2023 in Review
36 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q4 2023, worth a combined $22.6M — up 114% from $10.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ANVS positions and 5 closed out — a net gain of 6 holders — while 10 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $699K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $464K sold.
- 36 institutional investors held Annovis Bio (ANVS) as of Q4 2023, up from 30 in Q3 2023.
- Funds reported $22.6M of Annovis Bio stock for Q4 2023, up 114% quarter-over-quarter.
- 11 funds opened new Annovis Bio positions in Q4 2023 and 5 closed out, a net change of +6 holders.
- The largest Annovis Bio buyer in Q4 2023 was Vanguard Group, an estimated $699K added.
- The largest Annovis Bio seller in Q4 2023 was AIGH Capital Management, an estimated $464K sold.
Based on aggregated 13F filings for Q4 2023.